Deerland Probiotics & Enzymes’ DE111 probiotic attains published health claims in Australia and New Zealand
Deerland Probiotics & Enzymes attained a list of published health claims following the inclusion of its DE111 probiotic as a food ingredient under the Food Standards Australia New Zealand (FSANZ) Code.
Photo © Shutterstock.com/AlexLMX
Deerland Probiotics & Enzymes (Kennesaw, GA) attained a list of published health claims following the inclusion of its Bacillus subtilis DE111 probiotic as a food ingredient under the Food Standards Australia New Zealand (FSANZ) Code. The published claims are the results of a comprehensive and systematic review of evidence of a causal food-health relationship.
The claims include “promotes growth of healthy gastrointestinal flora”, “supports growth of beneficial gut bacteria”, “supports and improves digestive health in children and adults”, and “reduces total blood cholesterol or blood LDL cholesterol”.
DE111 also received a letter of no-objection on its GRAS status from the U.S. Food and Drug Administration, non-Novel Food status in both Canada and Australia, and approval as a natural health ingredient by Health Canada.
“This opens up many opportunities for brands to meet the growing demand for probiotic products in Australia and New Zealand by enhancing their food and beverages with functionality, communicated through science-backed claims.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
